CoChat

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma

Open access

The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.

Abstract

The nongenetic mechanisms required to control tumor phenotypic plasticity and shape drug‐resistance remain unclear. We show here that the Aryl hydrocarbon Receptor (AhR) transcription factor directly regulates the gene expression program associated with the acquisition of resistance to BRAF inhibitor (BRAFi) in melanoma. In addition, we show in melanoma cells that canonical activation of AhR mediates the activation of the SRC pathway and promotes the acquisition of an invasive and aggressive resistant phenotype to front‐line BRAFi treatment in melanoma. This nongenetic reprogramming identifies a clinically compatible approach to reverse BRAFi resistance in melanoma. Using a preclinical BRAFi‐resistant PDX melanoma model, we demonstrate that SRC inhibition with dasatinib significantly re‐sensitizes melanoma cells to BRAFi. Together we identify the AhR/SRC axis as a new therapeutic vulnerability to trigger resistance and warrant the introduction of SRC inhibitors during the course of the treatment in combination with front‐line therapeutics to delay BRAFi resistance. This study reports that the AhR/SRC axis constitutes a therapeutic vulnerability in BRAFi‐resistant melanoma. This study reports that the AhR/SRC axis constitutes a therapeutic vulnerability in BRAFi‐resistant melanoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202215677

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Loss of AhR reduces the invasive phenotype of BRAFi‐resistant melanoma cells AVem sensitivity was established in BRAFi‐resistant SK28 cells before and after knockout out of AhR by CRISPR/Cas9, by cell density measurements for 4 days after treatment (every 2 days), with an increasing concentration of BRAFi (vemurafenib, dabrafenib, or encorafenib). The IC50 (M) was calculated using GraphPad (PRISM9.0®).B, CWound healing assays were performed using IBIDI® chambers to evaluate the role of the AhR on cell migration. Images of the wound were captured using an Axio Vert.A1 inverted microscope (Carl Zeiss®) at 5× magnification. The histogram represents the mean ± s.d. Wound closure was determined by measuring the distance between the edges of the wound at time 0 and 15 h (n = 3 independent technical experiments for each cell lines or conditions) and compared using unpaired t‐tests with the Sidak–Bonferroni method. (B) Results obtained with BRAFi‐sensitive or resistant SK28 cells KO for the AhR in the absence of treatment. (n = 3 independent technical experiments for each cell lines). (C) Results obtained for the migration assay (0–15 h) for SK28 R cells KO or not for the AhR after treatment or not with 10 μM CH‐223191. (n = 3 independent technical experiments for each cell lines or conditions, mean ± s.d.). Statistical analysis using unpaired t‐tests with the Sidak–Bonferroni method has been performed between the mean of the three independent experiments.DThree‐dimensional spheroid growth of BRAFi‐sensitive or resistant SK28 cells KO before or after knockout of AhR by CRISPR/Cas9 in the absence of treatment. Images were captured 4 days after implantation of the spheroids into collagen gel. (n = 4 independent technical experiments, mean ± s.d.).EThree‐dimensional spheroid growth of BRAFi‐resistant SK28 cells KO before or after knockout of AhR by CRISPR/Cas9 after daily treatment with the specific AhR inhibitor CH‐223191 (5 μM) for 1 week or in the absence of treatment. Images were captured 4 days after implantation of the spheroids into collagen gel. (n = 3 independent technical experiments, mean ± s.d.). Statistical analysis using unpaired t‐tests method has been performed with the Sidak–Bonferroni method, (P < 0.01 ##, **, P < 0.001 ###, ***). Source data are available online for this figure.
Figure 1 Loss of AhR reduces the invasive phenotype of BRAFi‐resistant melanoma cells AVem sensitivity was established in BRAFi‐resistant SK28 cells before and after knockout out of AhR by CRISPR/Cas9, by cell density measurements for 4 days after treatment (every 2 days), with an increasing concentration of BRAFi (vemurafenib, dabrafenib, or encorafenib). The IC50 (M) was calculated using GraphPad (PRISM9.0®).B, CWound healing assays were performed using IBIDI® chambers to evaluate the role of the AhR on cell migration. Images of the wound were captured using an Axio Vert.A1 inverted microscope (Carl Zeiss®) at 5× magnification. The histogram represents the mean ± s.d. Wound closure was determined by measuring the distance between the edges of the wound at time 0 and 15 h (n = 3 independent technical experiments for each cell lines or conditions) and compared using unpaired t‐tests with the Sidak–Bonferroni method. (B) Results obtained with BRAFi‐sensitive or resistant SK28 cells KO for the AhR in the absence of treatment. (n = 3 independent technical experiments for each cell lines). (C) Results obtained for the migration assay (0–15 h) for SK28 R cells KO or not for the AhR after treatment or not with 10 μM CH‐223191. (n = 3 independent technical experiments for each cell lines or conditions, mean ± s.d.). Statistical analysis using unpaired t‐tests with the Sidak–Bonferroni method has been performed between the mean of the three independent experiments.DThree‐dimensional spheroid growth of BRAFi‐sensitive or resistant SK28 cells KO before or after knockout of AhR by CRISPR/Cas9 in the absence of treatment. Images were captured 4 days after implantation of the spheroids into collagen gel. (n = 4 independent technical experiments, mean ± s.d.).EThree‐dimensional spheroid growth of BRAFi‐resistant SK28 cells KO before or after knockout of AhR by CRISPR/Cas9 after daily treatment with the specific AhR inhibitor CH‐223191 (5 μM) for 1 week or in the absence of treatment. Images were captured 4 days after implantation of the spheroids into collagen gel. (n = 3 independent technical experiments, mean ± s.d.). Statistical analysis using unpaired t‐tests method has been performed with the Sidak–Bonferroni method, (P < 0.01 ##, **, P < 0.001 ###, ***). Source data are available online for this figure.CC BY · PubMed Central
Figure 2 The activated form of AhR rescues the invasive and BRAFi‐resistant phenotype of melanoma cell lines AhR Protein levels in 501Mel CTR cells and those transduced with sgRNA targeting AhR (#1, #2) were analyzed by western blotting.BRAFi sensitivity was established in 501Mel cells or with endogenous overexpression of the constitutive form of the AhR (sgRNA, CRISPRi), by measuring cell density for 4 days after treatment (every 2 days), with an increasing concentration of BRAFi (vemurafenib). The IC50 (M) was calculated using GraphPad (PRISM9.0®). Statistical analysis (two‐way ANOVA) has been performed between the mean of four independent experiments (SK28R KO vs. SK28R) at different concentrations; P < 0.001 ***.Three‐dimensional spheroid growth of 501Mel cells. Images were captured 7 days after spheroid implantation (n = 3 independent technical experiments, mean ± s.d.). Each histogram represents the mean ± s.d. Comparisons with control were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.001 ***.AhR Protein levels in SK28R WT, KO, and KO CA‐AhR cells were analyzed by western blotting.BRAFi sensitivity was established in SK28R cells in the absence of AhR (SK28R KO (CRISPR‐Cas9) or after overexpression of the constitutive form of AhR (CA‐AhR), by measuring the cell density for 4 days after treatment (every 2 days), with increasing concentrations of BRAFi (vemurafenib). The IC50 (M) was calculated using GraphPad (PRISM9.0®). Statistical analysis (two‐way ANOVA) has been performed between the mean of four independent experiments (SK28R KO or SK28R KO CA‐AhR vs. SK28R) at different concentrations; P < 0.01 **, P < 0.001 ***.Three‐dimensional spheroid growth of SK28 cells KO or not for AhR by CRISPR/Cas9 and rescued by the constitutive active form of AhR (KO CA‐AhR). Images were captured 4 days after spheroid implantation (n = 3 independent technical experiments, mean ± s.d.). Comparisons were performed using unpaired t‐tests with the Sidak–Bonferroni method.Expression heatmap for various gene signatures (established by the median of expression for specific genes) (invasive vs. proliferative, alpha, beta, resistant, melanocytic, transitory, neural crest‐like, and undifferentiated, see Appendix Table S1) in SK28 BRAFi‐sensitive or resistant cell lines KO or not for AhR by CRISPR/Cas9 and rescue with the constitute active form of AhR (KO CA‐AhR; GSE166617). Genes and clusters with similar expression profiles across the cohort are placed close to each other in the grid. The scale corresponds to the Z scores. Source data are available online for this figure.
Figure 2 The activated form of AhR rescues the invasive and BRAFi‐resistant phenotype of melanoma cell lines AhR Protein levels in 501Mel CTR cells and those transduced with sgRNA targeting AhR (#1, #2) were analyzed by western blotting.BRAFi sensitivity was established in 501Mel cells or with endogenous overexpression of the constitutive form of the AhR (sgRNA, CRISPRi), by measuring cell density for 4 days after treatment (every 2 days), with an increasing concentration of BRAFi (vemurafenib). The IC50 (M) was calculated using GraphPad (PRISM9.0®). Statistical analysis (two‐way ANOVA) has been performed between the mean of four independent experiments (SK28R KO vs. SK28R) at different concentrations; P < 0.001 ***.Three‐dimensional spheroid growth of 501Mel cells. Images were captured 7 days after spheroid implantation (n = 3 independent technical experiments, mean ± s.d.). Each histogram represents the mean ± s.d. Comparisons with control were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.001 ***.AhR Protein levels in SK28R WT, KO, and KO CA‐AhR cells were analyzed by western blotting.BRAFi sensitivity was established in SK28R cells in the absence of AhR (SK28R KO (CRISPR‐Cas9) or after overexpression of the constitutive form of AhR (CA‐AhR), by measuring the cell density for 4 days after treatment (every 2 days), with increasing concentrations of BRAFi (vemurafenib). The IC50 (M) was calculated using GraphPad (PRISM9.0®). Statistical analysis (two‐way ANOVA) has been performed between the mean of four independent experiments (SK28R KO or SK28R KO CA‐AhR vs. SK28R) at different concentrations; P < 0.01 **, P < 0.001 ***.Three‐dimensional spheroid growth of SK28 cells KO or not for AhR by CRISPR/Cas9 and rescued by the constitutive active form of AhR (KO CA‐AhR). Images were captured 4 days after spheroid implantation (n = 3 independent technical experiments, mean ± s.d.). Comparisons were performed using unpaired t‐tests with the Sidak–Bonferroni method.Expression heatmap for various gene signatures (established by the median of expression for specific genes) (invasive vs. proliferative, alpha, beta, resistant, melanocytic, transitory, neural crest‐like, and undifferentiated, see Appendix Table S1) in SK28 BRAFi‐sensitive or resistant cell lines KO or not for AhR by CRISPR/Cas9 and rescue with the constitute active form of AhR (KO CA‐AhR; GSE166617). Genes and clusters with similar expression profiles across the cohort are placed close to each other in the grid. The scale corresponds to the Z scores. Source data are available online for this figure.CC BY · PubMed Central
Figure 3 AhR regulates the expression of genes associated with the BRAFi‐resistant/dedifferentiated phenotype of melanoma Workflow for the identification of AhR regulated genes among signatures.Expression heatmap for the for the most highly enriched genes (n = 50; Appendix Fig S2B and C) from BRAFi‐sensitive/proliferation/differentiation (green) or BRAFi resistance/invasion/dedifferentiation signatures (red) in SK28 BRAFi‐sensitive or resistant cell lines KO or not for AhR by CRISPR/Cas9 and rescued by the constitute active form of AhR (KO CA‐AhR; GSE166617), BRAFi‐sensitive or BRAFi‐resistant melanoma cell lines from the Cancer Cell Line Encyclopedia (CCLE; Barretina et al, 2012) and melanoma cell lines from the Graeber datasets (Tsoi et al, 2018). The enrichment rank for the signatures are available in Dataset EV1.Expression heatmap for the most highly enriched genes (n = 50) in SK28R WT, KO, and KO CA‐AhR cells.Expression heatmap for the median expression of the most highly enriched genes after GSEA for 9 BRAFi‐treated melanoma patients during melanoma progression (pre‐treatment, during disease progression DP1 n = 9, DP2 n = 9, DP3 n = 5; GSE65185 (Hugo et al, 2015)). Clinical data are available in supplemental Table S1 from Hugo et al (2015). The scale corresponds to the Z scores.
Figure 3 AhR regulates the expression of genes associated with the BRAFi‐resistant/dedifferentiated phenotype of melanoma Workflow for the identification of AhR regulated genes among signatures.Expression heatmap for the for the most highly enriched genes (n = 50; Appendix Fig S2B and C) from BRAFi‐sensitive/proliferation/differentiation (green) or BRAFi resistance/invasion/dedifferentiation signatures (red) in SK28 BRAFi‐sensitive or resistant cell lines KO or not for AhR by CRISPR/Cas9 and rescued by the constitute active form of AhR (KO CA‐AhR; GSE166617), BRAFi‐sensitive or BRAFi‐resistant melanoma cell lines from the Cancer Cell Line Encyclopedia (CCLE; Barretina et al, 2012) and melanoma cell lines from the Graeber datasets (Tsoi et al, 2018). The enrichment rank for the signatures are available in Dataset EV1.Expression heatmap for the most highly enriched genes (n = 50) in SK28R WT, KO, and KO CA‐AhR cells.Expression heatmap for the median expression of the most highly enriched genes after GSEA for 9 BRAFi‐treated melanoma patients during melanoma progression (pre‐treatment, during disease progression DP1 n = 9, DP2 n = 9, DP3 n = 5; GSE65185 (Hugo et al, 2015)). Clinical data are available in supplemental Table S1 from Hugo et al (2015). The scale corresponds to the Z scores.CC BY · PubMed Central
Figure EV1 Role of AhR in the regulation of gene expression in SK28 melanoma cell lines Protein levels of AhR were analyzed by western blotting in BRAFi‐sensitive or resistant SK28 cells invalidated or not for the AhR and quantified using Fiji® relative to the level of HSC70 protein.Volcano plot combining the magnitude of the fold change (ratio of expression) between SK28S (green), R (red) wild‐type, or invalidated for AhR (KO) and the P‐values.Venn diagram representing the overlap between the differentially expressed genes between SK28 R vs. R (Fig 2D), SK28S vs. SKO, and SK28R vs. RKO.Expression heatmap of the median expression (n = 2; RT‐qPCR) for AhR target genes (invasion) in 501Mel CTR cells and those transduced with sgRNA targeting AhR (#1, #2). The scale corresponds to the Z scores. Source data are available online for this figure.
Figure EV1 Role of AhR in the regulation of gene expression in SK28 melanoma cell lines Protein levels of AhR were analyzed by western blotting in BRAFi‐sensitive or resistant SK28 cells invalidated or not for the AhR and quantified using Fiji® relative to the level of HSC70 protein.Volcano plot combining the magnitude of the fold change (ratio of expression) between SK28S (green), R (red) wild‐type, or invalidated for AhR (KO) and the P‐values.Venn diagram representing the overlap between the differentially expressed genes between SK28 R vs. R (Fig 2D), SK28S vs. SKO, and SK28R vs. RKO.Expression heatmap of the median expression (n = 2; RT‐qPCR) for AhR target genes (invasion) in 501Mel CTR cells and those transduced with sgRNA targeting AhR (#1, #2). The scale corresponds to the Z scores. Source data are available online for this figure.CC BY · PubMed Central
Figure 4 Canonical activation of AhR induces the activation of SRC/FAK associated with an increased activation of the focal adhesion pathway in BRAFi‐resistant and dedifferentiated melanoma cell lines At the basal level, AhR is located at the membrane layer in a protein complex that includes HSP90, p23, XAP, and SRC. Immunoprecipitation of SRC was performed with specific antibodies and SRC/AhR interaction analyzed by western blotting.Protein levels of the AhR, p‐SRC (Y416), SRC, p‐FAK (Y576/577), and FAK in the four different melanoma cell lines (n = 3). The level of BRAFi resistance corresponds to our measure of IC50 (Vemurafenib) for the different cell lines 501Mel (0.23 μM), SKMel28 (0.29 μM), M229 (0.89 μM), and M238 (2.16 μM). These cell lines correspond to the sensitive parental cells.Protein levels of the AhR, p‐SRC (Y416), SRC, p‐FAK (Y576/577), and FAK in the SK28R cell line KO or not for AhR by CRISPR/Cas9 or after rescue with the activated‐form of the AhR (CA‐AhR).Protein levels of AhR, p‐SRC (Y416), and SRC, in the SK28R cell line after treatment with different AhR ligands for 24 h (5 μM BaP, 5 μM indirubin, 5 μM ITE, 10 nM TCDD, and 5 μM FICZ).Protein levels of AhR, p‐SRC (Y416), and SRC, in the SK28R cell line after 24 h of treatment with increasing doses of ITE.Expression heatmap for SRC, FAK, focal‐adhesion, and integrin signatures in four different BRAFi‐sensitive and resistant melanoma cell lines.Expression heatmap for SRC, FAK, focal‐adhesion, and integrin signatures in the SK28R cell line KO or not for AhR by CRISPR/Cas9 or after rescue with the activated‐form of the AhR (CA‐AhR). The scale corresponds to the Z scores. Source data are available online for this figure.
Figure 4 Canonical activation of AhR induces the activation of SRC/FAK associated with an increased activation of the focal adhesion pathway in BRAFi‐resistant and dedifferentiated melanoma cell lines At the basal level, AhR is located at the membrane layer in a protein complex that includes HSP90, p23, XAP, and SRC. Immunoprecipitation of SRC was performed with specific antibodies and SRC/AhR interaction analyzed by western blotting.Protein levels of the AhR, p‐SRC (Y416), SRC, p‐FAK (Y576/577), and FAK in the four different melanoma cell lines (n = 3). The level of BRAFi resistance corresponds to our measure of IC50 (Vemurafenib) for the different cell lines 501Mel (0.23 μM), SKMel28 (0.29 μM), M229 (0.89 μM), and M238 (2.16 μM). These cell lines correspond to the sensitive parental cells.Protein levels of the AhR, p‐SRC (Y416), SRC, p‐FAK (Y576/577), and FAK in the SK28R cell line KO or not for AhR by CRISPR/Cas9 or after rescue with the activated‐form of the AhR (CA‐AhR).Protein levels of AhR, p‐SRC (Y416), and SRC, in the SK28R cell line after treatment with different AhR ligands for 24 h (5 μM BaP, 5 μM indirubin, 5 μM ITE, 10 nM TCDD, and 5 μM FICZ).Protein levels of AhR, p‐SRC (Y416), and SRC, in the SK28R cell line after 24 h of treatment with increasing doses of ITE.Expression heatmap for SRC, FAK, focal‐adhesion, and integrin signatures in four different BRAFi‐sensitive and resistant melanoma cell lines.Expression heatmap for SRC, FAK, focal‐adhesion, and integrin signatures in the SK28R cell line KO or not for AhR by CRISPR/Cas9 or after rescue with the activated‐form of the AhR (CA‐AhR). The scale corresponds to the Z scores. Source data are available online for this figure.CC BY · PubMed Central
Figure EV2 Activation of SRC after canonical activation of AhR in melanoma cell lines AThe AhR‐SRC interaction was quantified by proximity ligation assay. Hoechst‐stained nucleus in blue (20× magnification).BQuantification of protein levels using ImageJ (Fiji) corresponding to Fig 4B (n = 3 biological experiments, mean ± s.d.).CQuantification of protein levels corresponding to Fig 4C (n = 3 biological experiments, mean ± s.d.).D, EProtein levels of the AhR, p‐SRC (Y416), and SRC were analyzed by western blotting in SK28 after various times of treatment with ITE (5 μM) and quantified using ImageJ (Fiji) (E).FHistogram showing the expression (RT‐qPCR) of THBS1 and MMP1 in SK28 after treatment by ITE (5 μM) at different times (n = 1). Source data are available online for this figure.
Figure EV2 Activation of SRC after canonical activation of AhR in melanoma cell lines AThe AhR‐SRC interaction was quantified by proximity ligation assay. Hoechst‐stained nucleus in blue (20× magnification).BQuantification of protein levels using ImageJ (Fiji) corresponding to Fig 4B (n = 3 biological experiments, mean ± s.d.).CQuantification of protein levels corresponding to Fig 4C (n = 3 biological experiments, mean ± s.d.).D, EProtein levels of the AhR, p‐SRC (Y416), and SRC were analyzed by western blotting in SK28 after various times of treatment with ITE (5 μM) and quantified using ImageJ (Fiji) (E).FHistogram showing the expression (RT‐qPCR) of THBS1 and MMP1 in SK28 after treatment by ITE (5 μM) at different times (n = 1). Source data are available online for this figure.CC BY · PubMed Central
Figure 5 Inhibition of the SRC pathway increases BRAFi sensitivity and prevents invasive phenotype of melanoma cells Heatmap of the percentage of cell viability in SKR (left) or SKR KO or SKR KO CA‐AhR (right) cells treated with a combination of increasing doses of vemurafenib (y) and bosutinib or dasatinib (1 μM). IC50 values are represented by black squares.Three‐dimensional spheroid growth of a 50%/50% mix of SK28R WT (in red) and KO cells (in green) over 5 days. Cells were treated or not with SRC inhibitors: bosutinib (1 μM) or dasatinib (1 μM) every 2 days (n = 3 independent technical experiments, mean ± s.d.). Comparisons with control (DMSO) were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.001 ***.Three‐dimensional spheroid growth of SK28R WT (in red) and KO cells (in green) over 5 days. Cells were treated or not with dasatinib (1 μM) in combination with ITE (5 μM) or TCDD (20 nM) every 2 days (n = 3 independent technical experiments, mean ± s.d.). Comparisons with control (DMSO) were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.05 *, P < 0.01 **. Comparisons were performed using unpaired t‐tests with the Sidak–Bonferroni method.Protein levels of AhR, p‐SRC (Y416), and SRC in the SK28R cell line after 24 h of treatment with ITE (5 μM) or SRC inhibitor (dasatinib; 1 μM).Evaluation of AhR transcriptional activity related to AhR/ARNT binding sites (XRE) using p3xXRE‐luciferase constructs. HaCat keratinocytes cells were exposed or not to 10 nM TCDD alone or in combination with increasing concentrations of dasatinib O/N (n = 3 independent technical experiments, mean ± s.d.). Comparisons with control (0) were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.05 *, P < 0.001 ***.Expression heatmap of the median of gene expression for the various signatures (left) and AhR target genes (right) from RNAseq datasets for SK28R cells treated or not for 24 h with SRC inhibitors: bosutinib (Bos, 1 μM) or dasatinib (Das, 1 μM). The scale corresponds to the Z scores. Source data are available online for this figure.
Figure 5 Inhibition of the SRC pathway increases BRAFi sensitivity and prevents invasive phenotype of melanoma cells Heatmap of the percentage of cell viability in SKR (left) or SKR KO or SKR KO CA‐AhR (right) cells treated with a combination of increasing doses of vemurafenib (y) and bosutinib or dasatinib (1 μM). IC50 values are represented by black squares.Three‐dimensional spheroid growth of a 50%/50% mix of SK28R WT (in red) and KO cells (in green) over 5 days. Cells were treated or not with SRC inhibitors: bosutinib (1 μM) or dasatinib (1 μM) every 2 days (n = 3 independent technical experiments, mean ± s.d.). Comparisons with control (DMSO) were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.001 ***.Three‐dimensional spheroid growth of SK28R WT (in red) and KO cells (in green) over 5 days. Cells were treated or not with dasatinib (1 μM) in combination with ITE (5 μM) or TCDD (20 nM) every 2 days (n = 3 independent technical experiments, mean ± s.d.). Comparisons with control (DMSO) were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.05 *, P < 0.01 **. Comparisons were performed using unpaired t‐tests with the Sidak–Bonferroni method.Protein levels of AhR, p‐SRC (Y416), and SRC in the SK28R cell line after 24 h of treatment with ITE (5 μM) or SRC inhibitor (dasatinib; 1 μM).Evaluation of AhR transcriptional activity related to AhR/ARNT binding sites (XRE) using p3xXRE‐luciferase constructs. HaCat keratinocytes cells were exposed or not to 10 nM TCDD alone or in combination with increasing concentrations of dasatinib O/N (n = 3 independent technical experiments, mean ± s.d.). Comparisons with control (0) were performed using unpaired t‐tests with the Sidak–Bonferroni method, P < 0.05 *, P < 0.001 ***.Expression heatmap of the median of gene expression for the various signatures (left) and AhR target genes (right) from RNAseq datasets for SK28R cells treated or not for 24 h with SRC inhibitors: bosutinib (Bos, 1 μM) or dasatinib (Das, 1 μM). The scale corresponds to the Z scores. Source data are available online for this figure.CC BY · PubMed Central
Figure EV3 SRC inhibitors sensitize melanoma cells to BRAFi treatment Protein levels of AhR, p‐SRC (Y416), and SRC in SK28R cells invalidated or not for AhR by CRISPR/Cas9 or after rescue with the activated‐form of the AhR (CA‐AhR) and after treatment for 24 h with an HSP90 inhibitor (HSP990, 10 nM) with or without two different SRC inhibitors: dasatinib (1 μM) or bosutinib (1 μM).Histogram representing the expression (RT‐qPCR) of THBS1 and MMP1 in SK28R and SR28R KO treated for 24 h with an HSP90 inhibitor (HSP990, 10 nM) with or without two different SRC inhibitors: dasatinib (1 μM) or bosutinib (1 μM; n = 3 biological experiments, mean ± s.d.).Heatmap of the percentage of cell viability of M229R (left) and M238R cells treated with a combination of increasing doses of vemurafenib (y) and bosutinib or dasatinib (1 μM). IC50 values are represented by black squares. Source data are available online for this figure.
Figure EV3 SRC inhibitors sensitize melanoma cells to BRAFi treatment Protein levels of AhR, p‐SRC (Y416), and SRC in SK28R cells invalidated or not for AhR by CRISPR/Cas9 or after rescue with the activated‐form of the AhR (CA‐AhR) and after treatment for 24 h with an HSP90 inhibitor (HSP990, 10 nM) with or without two different SRC inhibitors: dasatinib (1 μM) or bosutinib (1 μM).Histogram representing the expression (RT‐qPCR) of THBS1 and MMP1 in SK28R and SR28R KO treated for 24 h with an HSP90 inhibitor (HSP990, 10 nM) with or without two different SRC inhibitors: dasatinib (1 μM) or bosutinib (1 μM; n = 3 biological experiments, mean ± s.d.).Heatmap of the percentage of cell viability of M229R (left) and M238R cells treated with a combination of increasing doses of vemurafenib (y) and bosutinib or dasatinib (1 μM). IC50 values are represented by black squares. Source data are available online for this figure.CC BY · PubMed Central
Figure 6 Inhibition of SRC sensitizes melanoma to BRAFi treatment in a PDX model PDX model MEL006R (BRAFi resistant) was implanted in NMRI nude mice. Mice with tumors reaching 200 mm3 were treated daily with vehicle (n = 6), dabrafenib alone (Dab, Biorbyt, 30 mg/kg, n = 5) dasatinib alone (Das, Selleckchem, 30 mg/kg, n = 9) or in combination dabrafenib + dasatinib (Das before combo, 30 mg/kg, n = 12).PDX tumor volumes were measured every 2 days until reaching 1,500 mm3. Values correspond to the mean ± s.e.m. Statistical analysis (two‐way ANOVA) has been performed between the different experiments (Das or Das before combo vs. Dab) at different times. Stars represent time from when tumor size is significantly lower than group treated with BRAFi alone (Dabrafenib) P < 0.05 *, P < 0.01 **.Kaplan–Meier survival curve for MEL006R mice treated with the different drugs. Comparison of survival curves have been performed using the nonparametric Log‐rank (Mantel–Cox) test.Number of days to reach max tumor volume (endpoint point size). Values correspond to the median ± s.d. Non‐parametric Mann–Whitney t‐test for the different treatments was performed compared with vehicle ***P < 0.001.
Figure 6 Inhibition of SRC sensitizes melanoma to BRAFi treatment in a PDX model PDX model MEL006R (BRAFi resistant) was implanted in NMRI nude mice. Mice with tumors reaching 200 mm3 were treated daily with vehicle (n = 6), dabrafenib alone (Dab, Biorbyt, 30 mg/kg, n = 5) dasatinib alone (Das, Selleckchem, 30 mg/kg, n = 9) or in combination dabrafenib + dasatinib (Das before combo, 30 mg/kg, n = 12).PDX tumor volumes were measured every 2 days until reaching 1,500 mm3. Values correspond to the mean ± s.e.m. Statistical analysis (two‐way ANOVA) has been performed between the different experiments (Das or Das before combo vs. Dab) at different times. Stars represent time from when tumor size is significantly lower than group treated with BRAFi alone (Dabrafenib) P < 0.05 *, P < 0.01 **.Kaplan–Meier survival curve for MEL006R mice treated with the different drugs. Comparison of survival curves have been performed using the nonparametric Log‐rank (Mantel–Cox) test.Number of days to reach max tumor volume (endpoint point size). Values correspond to the median ± s.d. Non‐parametric Mann–Whitney t‐test for the different treatments was performed compared with vehicle ***P < 0.001.CC BY · PubMed Central
Figure EV4 Impact of inhibition of SRC to sensitize PDX melanoma to BRAFi treatment PDX model MEL006R (BRAFi resistant) was implanted in NMRI nude mice. Mice with tumors reaching 200 mm3 were treated daily with vehicle (n = 6), dabrafenib alone (Dab, Biorbyt, 30 mg/kg, n = 5) dasatinib alone (Das, Selleckchem, 30 mg/kg, n = 9) or in combination dabrafenib + dasatinib (Das before combo, 30 mg/kg, n = 12). PDX tumor volumes were measured every 2 days until reaching 1,500 mm3.IHC for AHR and P‐SRC PDX model MEL006R representative for each group of treatment in order to confirm the action of SRCi to specifically prevent phosphorylation of SRC. Quantification of % of positive immunostaining area has been performed using ImageJ (Fiji) after integration of specific signal. Semi‐quantitative analysis of optical density for several tumors for each group (n = 4) has been performed after calibration of the image using step tablet (Fiji).
Figure EV4 Impact of inhibition of SRC to sensitize PDX melanoma to BRAFi treatment PDX model MEL006R (BRAFi resistant) was implanted in NMRI nude mice. Mice with tumors reaching 200 mm3 were treated daily with vehicle (n = 6), dabrafenib alone (Dab, Biorbyt, 30 mg/kg, n = 5) dasatinib alone (Das, Selleckchem, 30 mg/kg, n = 9) or in combination dabrafenib + dasatinib (Das before combo, 30 mg/kg, n = 12). PDX tumor volumes were measured every 2 days until reaching 1,500 mm3.IHC for AHR and P‐SRC PDX model MEL006R representative for each group of treatment in order to confirm the action of SRCi to specifically prevent phosphorylation of SRC. Quantification of % of positive immunostaining area has been performed using ImageJ (Fiji) after integration of specific signal. Semi‐quantitative analysis of optical density for several tumors for each group (n = 4) has been performed after calibration of the image using step tablet (Fiji).CC BY · PubMed Central
Figure EV5 Canonical activation of AhR leads to activation of the SRC/EGFR axis in melanoma cells Protein levels of AhR, p‐SRC (Y416, Y530), SRC, p‐EGFR (Y1068, Y845) and EGFR were analyzed by western blotting in SK28R cells treated or not with ITE (5 μM, 24 h).Protein levels of AhR, p‐SRC (Y416), SRC, p‐EGFR (Y845), and EGFR, in the SK28R cell line after treatment with different AhR ligands for 24 h (10 nM TCDD, 5 μM BaP, 5 μM FICZ and 5 μM indirubin).Protein levels of AhR, p‐SRC (Y416), SRC, p‐EGFR (Y845) and EGFR were analyzed by western blotting in SK28R cells treated or not with ITE (5 μM, 24 h) with or not AhR inhibitor (CH‐223191, 5 μM), Src inhibitor: dasatinib (0.5 μM) and EGFR inhibitor: gefitinib (20 μM).Heatmap of the percentage of cell viability in SKR cells treated with a combination of increasing doses of vemurafenib (y) and erlotinib (left) or gefitinib (right) (1 μM). IC50 values are represented by black squares. Source data are available online for this figure.
Figure EV5 Canonical activation of AhR leads to activation of the SRC/EGFR axis in melanoma cells Protein levels of AhR, p‐SRC (Y416, Y530), SRC, p‐EGFR (Y1068, Y845) and EGFR were analyzed by western blotting in SK28R cells treated or not with ITE (5 μM, 24 h).Protein levels of AhR, p‐SRC (Y416), SRC, p‐EGFR (Y845), and EGFR, in the SK28R cell line after treatment with different AhR ligands for 24 h (10 nM TCDD, 5 μM BaP, 5 μM FICZ and 5 μM indirubin).Protein levels of AhR, p‐SRC (Y416), SRC, p‐EGFR (Y845) and EGFR were analyzed by western blotting in SK28R cells treated or not with ITE (5 μM, 24 h) with or not AhR inhibitor (CH‐223191, 5 μM), Src inhibitor: dasatinib (0.5 μM) and EGFR inhibitor: gefitinib (20 μM).Heatmap of the percentage of cell viability in SKR cells treated with a combination of increasing doses of vemurafenib (y) and erlotinib (left) or gefitinib (right) (1 μM). IC50 values are represented by black squares. Source data are available online for this figure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 85 references

Cited by

See all 26

Metadata

Authors
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • VIB-KU Leuven Center for Cancer Biology (BE)
Corresponding author
  • Galibert, Marie‐Dominique
  • Corre, Sébastien
Venue
EMBO Molecular Medicine
Published
2022-10-28
Volume
14
Issue
12
Pages
e15677-e15677
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W4307492590
Cited by
26
References
87
Citations by year
2026: 6 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 4
FWCI
1.63
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Molecular Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Association Recherche Contre le Cancer (PGA1*20160203868)
  • Centre National de la Recherche Scientifique
  • FHU CAMIn‐CHU RENNES
  • Institut National de la Santé et de la Recherche Médicale
  • Institut National Du Cancer (ENV201308, ENV201603)
  • Ligue Contre le Cancer
  • Stichting Tegen Kanker (2016‐054)
  • Université de Rennes 1
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
aryl hydrocarbon receptor, BRAF inhibitor resistance, melanoma, dasatinib, therapeutic vulnerabilities, transcriptional reprogramming, patient-derived xenografts
MeSH terms
Dasatinib, Humans, Melanoma, Phenotype, Receptors, Aryl Hydrocarbon, Protein Kinase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma. https://app.cochat.ai/papers/10.15252/emmm.202215677
The paper
Paris, A., Tardif, N., Baietti, F. M., Berra, C., Leclair, H. M., Leucci, E., Galibert, M., & Corre, S. (2022). The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202215677

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.